Assessment of Early-detection Based on Liquid Biopsy in Lung Cancer (ASCEND-LUNG)

NCT04817046 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 467

Last updated 2021-03-25

No results posted yet for this study

Summary

The purpose of this study is to develop a lung cancer diagnosis tool using a multi-omics approach based on liquid biopsy.

Conditions

Sponsors & Collaborators

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Fan Yang, MD · Peking University People's Hospital

Eligibility

Min Age
40 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-19
Primary Completion
2022-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04817046 on ClinicalTrials.gov